The Prostate

Funding information National Natural Science Foundation of China, Grant/Award Number: 30950011 Abstract Background: The amplification of gene COPS3 is closely related to the development of osteosarcoma and hepatocellular carcinoma. However, the effects of COPS3 on prostate cancer (PCa) are poorly understood. Methods: In this study, the protein expression of COPS3 in PCa tissues, adjacent normal tissues, and bone metastasis tissues of PCa was analyzed by immunohistochemistry. Furthermore, cell proliferation, colony formation, migration, and invasion assay were performed in 22rv1 and PC‐3 cells after knocking down COPS3 by small interfering RNAs. Furthermore, we performed western blot analysis to explore the potential mechanisms underlying it. Results: This study found that the overall survival of the COPS3 high‐expression group was significantly shorter than the low‐expression group. This study discovered that the protein expression of COPS3 in PCa tissues was higher than that in the matched nontumor prostate tissues. In addition, tissues from bone metastasis of PCa had a high percentage of overexpressing COPS3. After knockdown of the COPS3 gene in 22rv1 and PC3 cells, two classic human PCa cell lines which had a high level of COPS3, the abilities of migration, invasion, and proliferation were inhibited. Finally, protein levels of phosphorylated P38 mitogen‐activated protein kinase (MAPK) and N‐cadherin were significantly decreased after knocking down the expression of COPS3, and the protein levels of E‐cadherin were significantly increased. Conclusions: In conclusion, COPS3 may be closely related to the progress of PCa. Knockdown of COPS3 inhibited the progress of PCa through reducing the levels of phosphorylated P38 MAPK and impaired the epithelial‐mesenchymal transition process.

[1]  Xiaobo Huang,et al.  Knockdown of COPS3 inhibits the progress of prostate cancer through reducing phosphorylated p38 MAPK expression and impairs the epithelial-mesenchymal transition process. , 2019 .

[2]  D. Duggan,et al.  Concept and benchmarks for assessing narrow‐sense validity of genetic risk score values , 2019, The Prostate.

[3]  Matthew S. Lebo,et al.  Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood , 2019, Cell.

[4]  Yang Ni,et al.  Polygenic prediction via Bayesian regression and continuous shrinkage priors , 2018, Nature Communications.

[5]  Mary E. Haas,et al.  Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.

[6]  K. D. Sørensen,et al.  Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci , 2018, Nature Genetics.

[7]  Xiaobo Huang,et al.  Overexpression of COPS3 promotes clear cell renal cell carcinoma progression via regulation of Phospho–AKT(Thr308), Cyclin D1 and Caspase–3 , 2018, Experimental cell research.

[8]  F. Gao,et al.  Osteocalcin Induces Proliferation via Positive Activation of the PI3K/Akt, P38 MAPK Pathways and Promotes Differentiation Through Activation of the GPRC6A-ERK1/2 Pathway in C2C12 Myoblast Cells , 2017, Cellular Physiology and Biochemistry.

[9]  H. Akça,et al.  The crosstalk between p38 and Akt signaling pathways orchestrates EMT by regulating SATB2 expression in NSCLC cells , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[10]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[11]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[12]  Wen-fang Chen,et al.  Neuroprotective properties of icariin in MPTP-induced mouse model of Parkinson's disease: Involvement of PI3K/Akt and MEK/ERK signaling pathways. , 2017, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[13]  J. Finek,et al.  [Epithelial-mesenchymal Transition in Tumor Tissue and Its Role for Metastatic Spread of Cancer]. , 2017, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

[14]  Helen E. Parkinson,et al.  The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog) , 2016, Nucleic Acids Res..

[15]  E. Altmann,et al.  Targeted inhibition of the COP9 signalosome for treatment of cancer , 2016, Nature Communications.

[16]  I. Thompson,et al.  Adding genetic risk score to family history identifies twice as many high‐risk men for prostate cancer: Results from the prostate cancer prevention trial , 2016, The Prostate.

[17]  Haitao Chen,et al.  Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer , 2016, Asian journal of andrology.

[18]  W. I. Mohamed,et al.  Cullin–RING ubiquitin E3 ligase regulation by the COP9 signalosome , 2016, Nature.

[19]  Sean M. Wu,et al.  Cardioprotective Actions of TGFβRI Inhibition Through Stimulating Autocrine/Paracrine of Survivin and Inhibiting Wnt in Cardiac Progenitors , 2016, Stem cells.

[20]  Martin Eklund,et al.  Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. , 2015, The Lancet. Oncology.

[21]  M. Eisenstein,et al.  CSNAP Is a Stoichiometric Subunit of the COP9 Signalosome. , 2015, Cell reports.

[22]  P. Visscher,et al.  Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores , 2015, bioRxiv.

[23]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[24]  Mong-Hong Lee,et al.  COP9 signalosome subunit 6 (CSN6) regulates E6AP/UBE3A in cervical cancer , 2015, Oncotarget.

[25]  Pui-Yan Kwok,et al.  A large multiethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences. , 2015, Cancer discovery.

[26]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[27]  Jianfeng Xu,et al.  Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk‐associated SNPs , 2013, The Prostate.

[28]  E. Bleecker,et al.  Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. , 2012, European urology.

[29]  G. Zang,et al.  Inhibition of Csn3 expression induces growth arrest and apoptosis of hepatocellular carcinoma cells , 2012, Cancer Chemotherapy and Pharmacology.

[30]  R. Zhao,et al.  Roles of COP9 signalosome in cancer , 2011, Cell cycle.

[31]  D. Shen,et al.  RNAi-mediated COPS3 gene silencing inhibits metastasis of osteogenic sarcoma cells , 2011, Cancer Gene Therapy.

[32]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[33]  Amanda Doucette,et al.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.

[34]  Pär Stattin,et al.  Cumulative association of five genetic variants with prostate cancer. , 2008, The New England journal of medicine.

[35]  P. Donnelly,et al.  A new multipoint method for genome-wide association studies by imputation of genotypes , 2007, Nature Genetics.

[36]  S. Bull,et al.  COPS3 amplification and clinical outcome in osteosarcoma , 2007, Cancer.

[37]  J. Lupski,et al.  COP9 Signalosome Subunit 3 Is Essential for Maintenance of Cell Proliferation in the Mouse Embryonic Epiblast , 2003, Molecular and Cellular Biology.

[38]  P. Patel,et al.  Hemizygosity for the COP9 signalosome subunit gene, SGN3, in the Smith-Magenis syndrome. , 1999, American journal of medical genetics.

[39]  X. Deng,et al.  Making sense of the COP9 signalosome. A regulatory protein complex conserved from Arabidopsis to human. , 1999, Trends in genetics : TIG.

[40]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[41]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[42]  Y. Mandel-Gutfreund,et al.  SFmap: a web server for motif analysis and prediction of splicing factor binding sites , 2010, Nucleic Acids Res..

[43]  Alexander Gheldof,et al.  Cadherins and epithelial-to-mesenchymal transition. , 2013, Progress in molecular biology and translational science.

[44]  A. Rezapour,et al.  ASSESSMENT OF SOME POTENTIAL RISK FACTORS OF POSTPARTUM DEPRESSION , 2009 .

[45]  N. Dubrawsky.  Cancer statistics , 2022 .

[46]  Genome-wide association studies of cancer: current insights and future perspectives , 2022 .